VLP@Silica |
|
Vaxjo ID |
282 |
|
Vaccine Adjuvant Name |
VLP@Silica |
|
Alternative Names |
Virus-like particle-templated silica-adjuvanted nanovaccine |
|
Adjuvant VO ID |
VO_0005770
|
|
Description |
A nanovaccine platform where virus-like particles (VLPs) serve as biotemplates to grow a silica coating, forming raspberry-like nanoparticles that enhance humoral and cellular immune responses |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
VLPs as the biotemplates to synthesize raspberry-like silica-adjuvanted VLP@Silica nanovaccines |
|
Structure |
Raspberry-like silica-coated VLPs, formed using APTES and TEOS on the VLP surface; final particles are spherical with a rough surface |
|
Appearance |
Spherical, raspberry-like nanoparticles |
|
Storage |
Stored at 4 °C after synthesis |
|
Preparation |
One-step synthesis using HBsAg or HPV VLPs with APTES and TEOS at 4 °C for 12 h, followed by washing |
|
Dosage |
HBsAg VLP@Silica: 2 μg antigen + 20 μg silica (per dose) HPV VLP@Silica: 4 μg antigen + 40 μg silica (per dose) |
|
Function |
VLP@Silica promote silica dissolution-induced lysosomal escape and cytosolic delivery of antigens, and enhance the secretion of both Th1 and Th2 type cytokines in murine bone marrow-derived dendritic cells (BMDCs). Additionally, they could improve antigen trafficking and mediate DC activation in draining lymph nodes (DLNs). |
|
Safety |
Demonstrated good safety profile in mice (no significant liver/kidney toxicity, no residual silica in organs at Day 28 post-vaccination) |
| References |
Li et al., 2022: Li M, Liang Z, Chen C, Yu G, Yao Z, Guo Y, Zhang L, Bao H, Fu D, Yang X, Wang H, Xue C, Sun B. Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity. ACS nano. 2022; 16(7); 10482-10495. [PubMed: 35763693].
|
